Characterization of pathway specific inhibitor response in pancreatic ductal adenocarcinoma in vitro models with different genetic backgrounds

Yixuan Ma

doi:10.18453/rosdok_id00004330

Yixuan Ma

Characterization of pathway specific inhibitor response in pancreatic ductal adenocarcinoma in vitro models with different genetic backgrounds

Universität Rostock, 2022

https://doi.org/10.18453/rosdok_id00004330

Abstract: Key proteins such as CK2, CDK, PI3K, AKT and KRAS are often considered as promising target molecules for therapeutic intervention strategies due to their important roles in the occurrence, development and prognosis of PDAC. The aim of this doctoral thesis was to explore the different effects of the above-mentioned key protein inhibitors on various PDAC cell lines, and to explore the effect of aberrations in the target genes of the inhibitors on the efficacy of the corresponding inhibitors by applying whole-exome sequencing (WES) and RNA sequencing (RNA-seq).

doctoral thesis free access

title:

Characterization of pathway specific inhibitor response in pancreatic ductal adenocarcinoma in vitro models with different genetic backgrounds

contributing persons:

Yixuan Ma[VerfasserIn]
	1294474375
Christian Junghanß[AkademischeR BetreuerIn]
	0000-0003-4707-777X
	118118587
	Universitätsmedizin Rostock
Matthias Sendler[AkademischeR BetreuerIn]
	0000-0001-6494-4105
	1025566920
	Universitätsmedizin Greifswald
Robert Jaster[AkademischeR BetreuerIn]
	122279085
	Universitätsmedizin Rostock

contributing corporate bodies:

Universität Rostock[Grad-verleihende Institution]
	38329-6
Universitätsmedizin Rostock[Grad-verleihende Institution]
	1029510660

abstract:

Key proteins such as CK2, CDK, PI3K, AKT and KRAS are often considered as promising target molecules for therapeutic intervention strategies due to their important roles in the occurrence, development and prognosis of PDAC. The aim of this doctoral thesis was to explore the different effects of the above-mentioned key protein inhibitors on various PDAC cell lines, and to explore the effect of aberrations in the target genes of the inhibitors on the efficacy of the corresponding inhibitors by applying whole-exome sequencing (WES) and RNA sequencing (RNA-seq). [English]

document type:

doctoral thesis

institution:

University Medicine

language:

English

subject class (DDC):

610 Medical sciences Medicine

publication /
production:

Rostock

Rostock: Universität Rostock

2022

statement of responsibility:

vorgelegt von Yixuan Ma

notes:

Enthält Zeitschriftenartikel

The results of the dissertation presented here have been published in peer-reviewed journals with impact factor points. Work I: Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Sender, S.; Sekora, A.; Kong, W.; Bauer, P.; Ameziane, N.; Krake, S.; Radefeldt, M.; Al-Ali, R.; Weiss, F.U.; Lerch, M.M.; Parveen, A.; Zechner, D.; Junghanss, C.; Murua Escobar, H. Int. J. Mol. Sci. 2022, 23, 4409. https://doi.org/10.3390/ijms23084409 Impact Factor 2022: 5.924; Work II: The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Sender, S.; Sekora, A.; Kong, W.; Bauer, P.; Ameziane, N.; Al-Ali, R.; Krake, S.; Radefeldt, M.; Weiss, F.U.; Lerch, M.M.; Parveen, A.; Zechner, D.; Junghanss, C.; Murua Escobar, H. Int. J. Mol. Sci. 2022, 23, 4295. https://doi.org/10.3390/ijms23084295 Impact Factor 2022: 5.924; Work III: Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Schulz, B.; Trakooljul, N.; Al Ammar, M.; Sekora, A.; Sender, S.; Hadlich, F.; Zechner, D.; Weiss, F.U.; Lerch, M.M.; Jaster, R.; Junhanss, C.; Murua Escobar, H. Cancers 2022, 14, 4467. https://doi.org/10.3390/cancers14184467 Impact Factor 2022: 6.575

identifiers: